Cinctive Capital Management LP Buys 23,119 Shares of Hologic, Inc. $HOLX

Cinctive Capital Management LP increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 53.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,404 shares of the medical equipment provider’s stock after acquiring an additional 23,119 shares during the period. Cinctive Capital Management LP’s holdings in Hologic were worth $4,482,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Hologic by 10.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock worth $2,395,000 after purchasing an additional 3,520 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Hologic by 27.7% during the 1st quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock valued at $1,081,000 after buying an additional 3,790 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Hologic in the 2nd quarter worth approximately $454,000. Allworth Financial LP lifted its position in Hologic by 120.3% in the 2nd quarter. Allworth Financial LP now owns 1,511 shares of the medical equipment provider’s stock worth $98,000 after buying an additional 825 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Hologic by 1.7% in the second quarter. Geode Capital Management LLC now owns 5,828,325 shares of the medical equipment provider’s stock worth $378,209,000 after buying an additional 97,142 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. BNP Paribas Exane lowered shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a report on Friday, November 21st. Finally, Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and decreased their target price for the stock from $79.00 to $78.00 in a research report on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $78.42.

Hologic Price Performance

HOLX opened at $75.12 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The stock’s 50 day simple moving average is $75.13 and its 200 day simple moving average is $72.72. The firm has a market cap of $16.77 billion, a price-to-earnings ratio of 31.30, a PEG ratio of 2.24 and a beta of 0.73. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $75.75.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share for the quarter, missing the consensus estimate of $1.09 by ($0.05). The company had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.87 EPS. As a group, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.